title: Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.
abstract: OBJECTIVE
  To determine whether genetic factors that influence age-related macular degeneration (AMD) have an early pharmacogenetic effect on treating exudative AMD with ranibizumab in a Korean population.
  
  
  METHODS
  A retrospective study of 102 patients (70 with typical neovascular AMD and 32 with polypoidal choroidal vasculopathy) with exudative AMD treated with intravitreal ranibizumab monotherapy was conducted. Optical coherence tomography, fluorescein, and indocyanine green angiography were taken at the baseline. The best-corrected visual acuity (BCVA) and the central subfield macular thickness (CSMT) were recorded at the baseline and at each monthly visit. The genotypes of the polymorphisms in the known AMD susceptibility loci (CFH, AMRS2, HTRA1, VEGFA, and KDR) were determined, and association between their frequencies and the changes in the BCVA and the CSMT were evaluated.
  
  
  RESULTS
  The mean baseline visual acuity was 0.96 ± 0.59 logMAR (approximately 20/200 in the Snellen equivalent), and the mean number of injections was 3.87 before the month 6 visit. No association was observed between the change in BCVA and each genotype. For the changes in the CSMT, a significant difference was observed only with the VEGF-A (rs833069) gene. The decrease in the CSMT at month 3 for the major allele homozygote AA genotype, the heterozygote AG genotype, and the risk allele homozygote GG genotype was 25.66 ± 85.40, 86.93 ± 92.31, and 85.30 ± 105.30 μm, respectively (p=0.012, p=0.044, and p=0.002 for AG, GG, and combined AG or GG genotype, respectively, compared to the AA genotype). This trend was maintained until month 6.
  
  
  CONCLUSIONS
  The VEGF-A (rs833069) polymorphism showed a significant association with the anatomic response to intravitreal ranibizumab. No significant difference was found between the genotype of the potential risk polymorphism for development of AMD and the early visual improvement after intravitreal ranibizumab.
authors.affiliation: Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, South Korea.
authors.forename: Woohyok
authors.initials: W
authors.lastname: Chang
authors.forename: Dong Hyoun
authors.initials: DH
authors.lastname: Noh
authors.forename: Min
authors.initials: M
authors.lastname: Sagong
authors.forename: In Taek
authors.initials: IT
authors.lastname: Kim
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D003710:Demography; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D008297:Male; D010597:Pharmacogenetics; D000069579:Ranibizumab; D056910:Republic of Korea; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
references.citation: N Engl J Med. 2006 Oct 5;355(14):1419-31
references.pmid: 17021318
references.citation: Science. 2005 Apr 15;308(5720):419-21
references.pmid: 15761120
references.citation: Science. 2005 Apr 15;308(5720):385-9
references.pmid: 15761122
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):653-62
references.pmid: 21387180
references.citation: Jpn J Ophthalmol. 2012 Mar;56(2):145-51
references.pmid: 22307775
references.citation: Ophthalmology. 2010 Aug;117(8):1567-70
references.pmid: 20378180
references.citation: Hum Mol Genet. 2005 Nov 1;14(21):3227-36
references.pmid: 16174643
references.citation: Br J Ophthalmol. 2009 May;93(5):610-3
references.pmid: 19091853
references.citation: Mol Vis. 2011 Apr 20;17:977-82
references.pmid: 21541271
references.citation: Invest Ophthalmol Vis Sci. 2009 Feb;50(2):586-91
references.pmid: 18936151
references.citation: Jpn J Ophthalmol. 2012 Jan;56(1):60-7
references.pmid: 21959923
references.citation: Ophthalmology. 2010 Sep;117(9):1769-74
references.pmid: 20471686
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1635-42
references.pmid: 21725716
references.citation: Am J Ophthalmol. 2004 Mar;137(3):486-95
references.pmid: 15013873
references.citation: Am J Ophthalmol. 2009 Jun;147(6):1037-41, 1041.e1-2
references.pmid: 19268887
references.citation: Am J Ophthalmol. 2012 Jul;154(1):164-173.e1
references.pmid: 22541932
references.citation: Ophthalmology. 2007 Oct;114(10):1868-75
references.pmid: 17628683
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 Oct;249(10):1449-58
references.pmid: 21494878
references.citation: Ophthalmology. 2007 Dec;114(12):2168-73
references.pmid: 18054635
references.citation: Trans Am Ophthalmol Soc. 2011 Dec;109:115-56
references.pmid: 22253485
references.citation: Br J Ophthalmol. 2012 Feb;96(2):208-12
references.pmid: 21558292
references.citation: Hum Genet. 2006 Aug;120(1):139-43
references.pmid: 16710702
references.citation: Exp Eye Res. 2007 Oct;85(4):425-30
references.pmid: 17714704
references.citation: Acta Ophthalmol. 2011 Jun;89(4):e344-9
references.pmid: 21232084
references.citation: Am J Hum Genet. 2005 Sep;77(3):389-407
references.pmid: 16080115
references.citation: Jpn J Ophthalmol. 2011 Sep;55(5):435-443
references.pmid: 21744122
references.citation: PLoS One. 2012;7(7):e42014
references.pmid: 22848690
references.citation: Retina. 2012 Jan;32(1):4-9
references.pmid: 21878851
references.citation: Hum Mol Genet. 2006 Oct 1;15(19):2955-61
references.pmid: 16940309
references.citation: Science. 2005 Apr 15;308(5720):421-4
references.pmid: 15761121
references.citation: Science. 2006 Nov 10;314(5801):989-92
references.pmid: 17053108
references.citation: Clin Exp Ophthalmol. 2008 Jul;36(5):437-42
references.pmid: 18939352